Michael Gladstone
Principal @ Atlas Venture
Boston, United States
Michael Gladstone is an associate in the life sciences group.Prior to joining Atlas in 2012, Michael was a senior associate consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. While at L.E.K. Michael also served as head of client development forInspire, a volunteer consulting firm staffed by junior consultants at L.E.K., Bain & Company, Parthenon, and Monitor Group. He led, designed, and organized teams of consultants for strategy projects for six non-profit organizations in the greater Boston area.Prior to that, Michael was a Massachusetts Life Sciences Center Fellow at Eutropics, a Dana Farber Cancer Institute spin out, where he helped develop BH3 domain focused therapeutics and companion diagnostics for multiple myeloma and other malignancies. Previously, Michael worked in the viral pathogenesis department of Beth Israel Deaconess Medical Center where he conducted research on cellular HIV vaccines with Harvard Medical School Professor Norman Letvin. His research focused on elucidating the role of interleukin-21 on the cellular immune response to viral antigens.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 44%
Last updated:
For AI agents: llms.txt
Industries Michael Gladstone invests in
Stages Michael Gladstone invests in
Countries Michael Gladstone invests in
Investment Focus
Industry
- Biotechnology 8 (50%)
- Life Science 4 (25%)
- Medical 3 (19%)
- Biopharma 2 (13%)
- Health Care 2 (13%)
Stage
- Series A 8 (50%)
- Series B 5 (31%)
- Seed 1 (6%)
- Funding Round 1 (6%)
Country
- United States 7 (44%)
- United Kingdom 2 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M / Series B / Jan 08, 2026 | |
Ethyreal Bio
|
Ethyreal Bio is an early-stage biotechnology company developing precision, mechanism-driven therapies for thyroid diseases with high unmet medical needs. | $41M / Series A / Jun 01, 2024 | |
Pheon Therapeutics
|
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $120M / Series B / May 21, 2024 | |
|
Diagonal Therapeutics
|
Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $128M / Series A / Apr 03, 2024 | |
SAPI
|
Our embedded credit solution provides platforms with a flexible end-to-end lending program that enables them to offer fast and attractive financing for their merchants, to grow their ecosystems and businesses. | Mar 28, 2023 | |
|
Pheon Therapeutics
|
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $68M / Series A / Sep 28, 2022 | |
Versanis Bio
|
Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistentlyand potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters. | $70M / Series A / Aug 31, 2021 | |
Day One Biopharmaceuticals
|
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $130M / Series B / Feb 10, 2021 | |
|
Day One Biopharmaceuticals
|
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of peopleof all ages living with cancer starting from the biology of childhood cancer.Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies.Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA. | $60M / Series A / May 21, 2020 | |
Third Harmonic Bio
|
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the externalenvironment and that act as the key mediator of the inflammation associated with allergic diseases. | $50M / Series A / Jan 01, 2019 | |
| See all 16 investments → | |||
Co-Investors
About Atlas Venture
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Atlas Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Chelsea Place Johnson
Principal
|
|||
Ed Holson
Entrepreneur-in-Residence
|
|||
Jean-Francois Formela
Partner
|
|||
Kevin Bitterman
Partner
|
|||
|
Michael Gladstone
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Gladstone invest in?
Michael Gladstone invests primarily in Biotechnology, Life Science and Medical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michael Gladstone last invest?
The most recent investment recorded for Michael Gladstone closed in Jan 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
